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Background: To describe the baseline characteristics of patients with heart failure and 
preserved left ventricular ejection fraction (HFpEF) enrolled in the PARAGON-HF (Prospective 
Comparison of ARNI with ARB Global Outcomes in HFpEF) trial comparing sacubitril/valsartan to 
valsartan in reducing morbidity and mortality. 
 
Methods and Results:  We report key demographic, clinical and laboratory findings, and 
baseline therapies, of 4,822 patients randomized in PARAGON-HF, stratified by factors that 
influence criteria for study inclusion.  We further compared baseline characteristics of patients 
enrolled in PARAGON-HF with those patients enrolled in other recent trials of HFpEF. 
Among patients enrolled from various regions (16% Asia-Pacific, 37% Central Europe, 7% 
Latin America, 12% North America, 28% Western Europe), the mean age of patients enrolled in 
PARAGON-HF was 72.7 ± 8.4 years, 52% of patients were female, and mean left ventricular 
ejection fraction was 57.5%, similar to other trials of HFpEF. Most patients were in NYHA Class 
II, and 38% had one or more hospitalizations for heart failure within the previous 9 months. 
Diabetes (43%) and chronic kidney disease (47%) were more prevalent than in previous trials of 
HFpEF. Many patients were prescribed ACE inhibitors or ARBs (85%), beta-blockers (80%), 
calcium-channel blockers (36%), and MRA (24%).  As specified in the protocol, virtually all 
patients were on diuretics, had elevated plasma concentrations of N-Terminal Pro B-Type 
Natriuretic peptide (median  911 pg/ml [IQR 464, 1610]), and structural heart disease. 
 
  
Conclusions: PARAGON-HF represents a contemporary group of patients with HFpEF with 
similar age and sex distribution compared to prior HFpEF trials, but higher prevalence of 
comorbidities. These findings provide insights into the impact of inclusion criteria on, and 
regional variation in, HFpEF patient characteristics.   








The clinical syndrome of heart failure with preserved ejection fraction (HFpEF) is 
characterized broadly by signs and symptoms of heart failure and in the absence of a reduced 
left ventricular ejection fraction1. Precise definition and diagnostic clinical criteria for HFpEF 
remain controversial but, for the purposes of inclusion in clinical trials, have become more 
stringent in recent years because of concerns about enrolling patients with other causes of 
dyspnea and edema misdiagnosed as heart failure2.  
 The PARAGON-HF trial is a large, double-blind randomized controlled clinical outcomes 
trial testing the hypothesis that sacubitril/valsartan, an angiotensin receptor neprilysin inhibitor 
(ARNIO) would be superior to valsartan in reducing morbidity and mortality in patients with 
HFpEF3. Sacubitril/valsartan simultaneously blocks the angiotensin II type I receptor and inhibits 
the enzyme neprilysin, a protease that plays a role in the breakdown of several vasoactive 
peptides including the biologically active natriuretic peptides. Compared to enalapril, 
sacubitril/valsartan conclusively reduced morbidity and mortality amongst patients with HFrEF 
in PARADIGM-HF4.  In a phase II trial of HFpEF, PARAMOUNT-HF,  sacubitril/valsartan compared 
with valsartan, reduced NT-proBNP at 12 weeks, and reduced both left atrial volume and New 
York Heat Association (NYHA) class at 36 weeks compared to valsartan5. These data provided 
the rationale for the design of PARAGON-HF, which was also heavily influenced by the 
experience gained from previous trials of HFpEF. In this report, we describe the baseline 
  
characteristics of patients enrolled in PARAGON-HF and compare them to patients enrolled in 




The data, analytic methods, and study materials will not be made available to other researchers 
for purposes of reproducing the results or replicating the procedure. 
 
Patients and Study Design 
PARAGON-HF is a randomized, double-blind, parallel group, active-controlled, two-arm 
event driven trial comparing the efficacy and safety of sacubitril/valsartan versus valsartan in 
patients with heart failure and preserved ejection fraction. PARAGON-HF enrolled patients with 
signs and symptoms of heart failure (NYHA Class II to IV), left ventricular ejection fraction (LVEF) 
of 45% or greater,  increased plasma concentrations of B-type  natriuretic peptides (degree of 
elevation depending on history of heart failure hospitalization within 9 months, and presence 
or absence of atrial fibrillation), and evidence of structural heart disease (increased left atrial 
size or left ventricular hypertrophy). Prior to randomization, patients entered sequential single-
blind run-in periods ensuring that both treatments were tolerated at half the target doses. The 
primary endpoint for the trial is cardiovascular death and total number of ( first and recurrent) 
heart failure hospitalizations. The trial is event driven and will stop when at least 1847 primary 
events are reached.  The study was approved by institutional review boards at individual study 
  
sites, and all patients signed written informed consent. The details of the study design are 
published3.  
Baseline characteristics were collected at screening and several of these were assessed 
again at randomization. We report baseline characteristics at screening for all variables unless 
otherwise stated, as screening represents a truer baseline because of the sequential run-in 
periods prior to randomization. Because plasma concentrations of NT-proBNP required for 
enrollment in PARAGON-HF differed based on the presence or absence of atrial fibrillation at 
screening, and whether or not patients had been hospitalized for heart failure within 9 months, 
we stratified baseline characteristics based on these measures. In addition, we stratified 
baseline characteristics based on region of origin: Asia-Pacific/Other, Central Europe, Latin 
America, North America or Western Europe. Finally, we compared baseline characteristics from 
PARAGON-HF with those of other HFpEF trials, including those patients enrolled in the Americas 
in TOPCAT6, I-Preserve7, CHARM-Preserved8 and PEP-CHF9, and with patients with HFrEF 
enrolled in the PARADIGM-HF trial4. Assessment in TOPCAT was confined to those patients 
enrolled in the Americas because of concern about enrollment of patients without clinical heart 
failure in those enrolled in Russia and the Republic of Georgia2. The MAGGIC risk score10, a 
validated risk score in heart failure, was calculated and compared amongst trials. Baseline 
characteristics are compared using t-tests or analysis of variance for continuous variables and 





Between July 18, 2014 and December 16, 2016, 11,302 patients were screened for 
inclusion in the study in 43 countries.  The most common reasons for screen failure were 
insufficient NT-proBNP (61%), elevated potassium (10%), eGFR below inclusion cutoff (6%), 
alternative diagnoses other than HFpEF (6%) and elevated LFTs (4%).  5754 patients who 
fulfilled inclusion and exclusion criteria entered valsartan run-in, and  of these,  544 did not 
complete the valsartan run-in phase. Subsequently,  5210 entered the sacubitril/valsartan run-
in phase, and of these, 388 did not complete the sacubitril/valsartan run-in phase. The most 
common reasons for run-in failure were predefined safety adverse events (hypotension, 
hyperkalemia, and renal dysfunction; 62%), subject decision (12%), protocol deviation (12%), 
non-compliance (6%), and death (5%). Ultimately, 4822 patients were randomized to 
sacubitril/valsartan or valsartan.  
 
Baseline characteristics of randomized patients are shown in Table 1, and signs and 
symptoms of heart failure in randomized patients are shown in Figure 1. Their median age was 
73 ± 8.4 years, 52% were women, most were in NYHA functional class II and the mean LVEF was 
58 ± 7.9%. Only 48% of patients had had a prior heart failure hospitalization and of these 
almost 80% had been in the previous 9 months. Nearly all (98%) patients had dyspnea on effort 
and many had fatigue (59%), edema (45%), orthopnea (22%), jugular venous distension (17%), 
rales (11%), paroxysmal nocturnal dyspnea (7.6%), and dyspnea at rest (4.6%). AF or flutter 
(33%) based on an ECG at the time of screening, diabetes (43%) and chronic kidney disease 
(47%) were all common. As required by the protocol, almost all patients were on diuretics and 
had structural heart disease, including left atrial enlargement in 92%, at screening. ACE 
  
inhibitors or ARB (85%), beta-blocker (80%) and mineralocorticoid receptor antagonist (24%) 
were commonly prescribed.  The median MAGGIC risk score was 20 (IQR 16 - 24).  
Patients who fulfilled inclusion criteria, entered run-in, but were not randomized, were 
slightly older, were slightly higher NYHA class, had lower systolic blood pressure, were more 
likely to have been hospitalized for heart failure, had higher NT-proBNP, lower eGFR, and had 
less use of ACEi, ARBs and beta-blockers (Table 1).  
Patients with AF (Table S1) were older, more likely to be men and had features 
suggesting more advanced heart failure, such as worse NYHA class, higher heart rate and lower 
blood pressure, substantially higher plasma concentrations of NT-proBNP (per protocol 
requirement) and MAGGIC risk score.  Patients with a history of hospitalization for heart failure 
within the previous 9 months (Table S2) were younger, had higher NYHA class and were more 
likely to be prescribed MRAs but had lower plasma concentrations of NT-proBNP (reflecting the 
lower threshold required for inclusion) and the MAGGIC Risk score was slightly, but 
significantly, lower.  
Patients in North America and Western Europe tended to be older (Table S3), and more 
likely to have AF. North Americans were mostly likely to have diabetes; BMI was highest in 
North America, and lowest in Asia. There were substantial differences in concomitant therapy 
by region. MRA use was nearly twice as high in Asia as in other regions. While ACE inhibitor or 
ARB use was similar overall between regions, the proportion of ACE inhibitor to ARB varied 
widely. Nitrate use was highest in North America and anticoagulant use was highest in Western 
Europe. The MAGGIC risk score was lowest in Central Europe and highest in North America and 
Western Europe.  
  
 In comparison with other trials of HFpEF (Table 2), patients enrolled in PARAGON-HF 
were of similar age, with the exception of CHARM-Preserved, which allowed inclusion of 
younger patients. More patients were in NYHA class II compared to previous trials. Entry blood 
pressure was similar to that in other trials except TOPCAT-Americas, which required patients to 
have SBP < 130mmHg at entry, and PEP-CHF, in which blood pressure was higher.  LVEF was 
similar to prior trials except for PEP-CHF, in which it was higher. The prevalence of diabetes and 
CKD were similar to that observed in TOPCAT Americas, but higher than in other trials.  
 Characteristics differed substantially from patients with HFrEF enrolled in PARADIGM-HF 
(Table S4). Patients enrolled in PARAGON-HF were older and much more likely to be women. 
Plasma concentrations of NT-proBNP were substantially higher in PARADIGM-HF perhaps, in 
part, due to different threshold values for inclusion. Patients in PARAGON-HF were more likely 
to be prescribed an ARB rather than an ACE inhibitor prior to screening but overall use of either 
an ACE-I or ARB was similar. Prescription of beta-blockers was similar in the two trials but 
patients in PARAGON-HF were much less likely to be prescribed an MRA. The overall MAGGIC 






PARAGON-HF is the most contemporary and largest outcomes trial for HFpEF conducted 
to date, with more stringent entry criteria than previous trials. The baseline characteristics of 
  
patients enrolled in PARAGON-HF are generally consistent with those in prior trials of HFpEF, 
although are reflective of the somewhat more stringent inclusion criteria than in prior trials, 
designed to exclude low-risk patients who might have little to gain from a novel intervention 
and to include patients with a higher rate of events.  
Similar to other HFpEF trials and epidemiological studies, those enrolled in PARAGON-HF 
were, on average, older than patients enrolled in trials of HFrEF and included a much higher 
proportion of women. The prevalence of comorbidities was high, including prior hypertension, 
diabetes, coronary artery disease, and AF. Despite capping enrolment of patients with AF, 33% 
had atrial fibrillation at enrollment and more than half had a history of AF, suggesting that 
paroxysmal AF is extremely common in HFpEF.  
All patients enrolled in PARAGON-HF following protocol amendment 2 were required to 
have increased plasma concentration of NT-proBNP, with thresholds based on whether or not 
they had AF at screening and whether or not they had been hospitalized for heart failure within 
the prior 9 months. Prior to this amendment, which occurred early during the course of 
recruitment, patients could be enrolled without an increased NT-proBNP if they had been 
hospitalized in the previous 9 months. Following the amendment, patients were required to 
have NT-proBNP >200 pg/ml if in sinus rhythm or >600 pg/ml if in AF, if they had been 
hospitalized; if they had not been hospitalized for heart failure in the previous 9 months, they 
were required to have an NT-proBNP >300 pg/ml if in SR, and >900 pg/ml if in AF. Only 136 
patients (< 3%) were enrolled who did not fulfill these NT-proBNP criteria. Because patients 
enrolled with a history of HF hospitalization could be included with a lower NT-proBNP, on 
  
average, the NT-proBNP and risk profile for this group was slightly lower than those in the 
subgroup that had not been hospitalized.  
Patients who fulfilled PARAGON inclusion criteria and entered run-in but were not 
randomized were slightly older, sicker and more comorbid than patients who were randomized. 
Not surprisingly, the most frequent reasons for failing run-in were adverse events such as 
hypotension, hyperkalemia and renal dysfunction which would be expected to be more likely in 
a frailer population. The run-in was designed to maximize adherence to study medication 
during the double-blind period, but ultimately excludes some patients who may have trouble 
tolerating the therapy at target doses. 
 
 
In general, patients with AF were more likely to have other characteristics suggestive of 
higher risk, and their MAGGIC risk scores were higher. The NT-proBNP requirement was tripled 
for patients with AF to avoid the criticism that increased NT-proBNP reflected AF rather than 
heart failure. While some risk factors were less prominent in patients who had had a heart 
failure hospitalization within 9 months, this was likely due to the fact that these patients had a 
lower NT-proBNP. Nevertheless, prior analyses suggest that these groups should carry a similar 
risk of events 11, and patients with both atrial fibrillation and elevation in NT-proBNP are likely 
to be at higher overall risk. Importantly, despite strong recommendations in guidelines <60% of 
patients with AF were reported to be treated with anti-coagulants, which may reflect strong 
regional differences in the use of anticoagulants in this population. 
  
Regional differences in characteristics of patients with HFpEF have been noted 
previously12. Patients in central Europe were slightly younger and tended to have less renal 
dysfunction and lower NT-proBNP than in other regions. There were some substantial 
differences in concomitant medication use by region. Patients in North America and Western 
Europe were less likely to use MRAs than other regions. ACE inhibitor use was particularly low 
in Asia. Overall those in Central Europe had the lowest MAGGIC risk scores, and those in North 
America and Western Europe had the highest risk scores.  
Differences in baseline characteristics between patients enrolled in PARAGON-HF and 
those enrolled in prior HFpEF trials, such as the higher prevalence of diabetes and renal 
dysfunction, may be, to some extent, a result of the more stringent entry criteria in PARAGON-
HF which required patients to have an increased in NT-proBNP and evidence of structural heart 
disease, or may reflect different regional distribution including more patients enrolled in the 
US. Diagnostic awareness and thresholds for renal dysfunction and diabetes mellitus may also 
have changed. The MAGGIC risk score, a well validated comprehensive measure of mortality 
risk in heart failure, was similar to that observed in TOPCAT-Americas and slightly higher than 
that observed in CHARM-Preserved. Interestingly, the PARAGON-HF MAGGIC risk score was 
similar to that observed in PARADIGM-HF, a trial of HFrEF, probably due to the greater average 
age of participants in PARAGON-HF. MRA use was higher than in previous trials, which may be a 
result of the TOPCAT trial which showed relatively favorable results for spironolactone, or may 
reflect inclusion of more Asian patients, in whom MRA use was especially high (40%). 
Guidelines recommend that patients with HFrEF should generally receive an ACEi an 
ARB or an ARNI, a beta-blocker and an MRA and indicate that there is no robust evidence that 
  
any of these agents is effective for patients with HFpEF. Accordingly, it might be thought that 
large differences in treatment patterns would be observed between HFrEF and HFpEF, yet the 
similarities seem as striking as the differences, an observation that has also been observed in 
registries 13. This might reflect a failure to distinguish amongst phenotypes in clinical practice, 
or the use of these agents to treat comorbid conditions such as hypertension, ischemic heart 
disease or atrial fibrillation.  
 
In summary, PARAGON-HF is the largest clinical outcomes trial in HfpEF conducted to 
date. Patient characteristics are largely similar to those enrolled in other HFpEF trials, and in 
HFpEF epidemiologic cohorts, although some differences in characteristics likely are due to the 
more stringent enrollment criteria in PARAGON-HF than prior trials, as well as some clear 
regional differences. PARAGON-HF will determine whether sacubitril/valsartan, which has 
previously been shown to benefit patients with HFrEF, will also reduce morbidity and mortality 
in HFpEF.   
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Table 1. Baseline Characteristics 
 
 Patients Who Entered Run-in 
But were not Randomized 
N = 917 
Randomized patients 
N = 4822 
p 
Demographics    
Age 74 ± 8 73 ± 8 0.004 
Female Sex 52% 52% 0.66 
NYHA Classification     <0.001 
II 65% 72%  
III 34% 27%  
IV 1% 1%  
Race   0.007 
Asian 13% 13%  
Black 3% 2%  
Caucasian 81% 82%  
Native American 0.3% 1%  
Other 3% 3%  
Physical Examination    
Sitting Pulse Rate (beats/min) 71 ± 13 70 ± 12 <0.001 
Sitting Systolic Blood Pressure (mmHg) 132 ±17 136± 15 <0.001 
Sitting Diastolic Blood Pressure (mmHg) 74 ±11 76 ± 11 <0.001 
BP category   <0.001 
Systolic BP <= 110 9% 4%  
  
Systolic BP 111-130 41% 35%  
Systolic BP 131-150 38% 46%  
Systolic BP 151 or greater 12% 15%  
    
    
Body Mass Index (kg/m2) 29.7 ±5.6 30.2 ± 5.0 0.003 
Obese (BMI > 30 kg/m2) 44% 49% 0.003 
    
    
Medical History    
Prior Heart Failure Hospitalization, 55% 48% <0.001 
HHF within 9 Months 45% 38% <0.001 
Hypertension 92% 96% <0.001 
coronary artery disease 41% 43% 0.22 
Myocardial Infarction 22% 23% 0.85 
Atrial Fibrillation/Atrial Flutter 35% 32% 0.13 
Left Bundle Branch Block 7% 7% 0.71 
Diabetes 43% 43% 0.82 
Stroke 10% 10% 0.83 
Current Smoker 7% 7% 0.80 
Chronic Obstructive Pulmonary Disease 15% 14% 0.56 
Laboratory Values    
N-Terminal proB-type natriuretic peptide 
(pg/mL), Plasma/Serum (median, IQR) 
Median 1062 (998, 1129)     Median 885 (863, 908) <0.001 
Ejection Fraction (%), mean ± SD 57 ±8 58 ± 8 0.19 
  
Estimated glomerular filtration rate 
(mL/min/1.73m2), mean ± SD 
58 ±20 63 ±19 <0.001 
eGFR category   <0.001 
< 45 mL/min/1.73m2 28% 18%  
≥ 45, < 60 mL/min/1.73m2 31% 29%  
≥ 60 mL/min/1.73m2 41% 53%  
    
Medical Therapies  at Baseline    
Diuretic 874    (95%)              4638    (96%)                   0.21 
Mineralocorticoid Receptor Antagonists  290    (32%)              1301    (27%)                   0.004 
ACE-inhibitors  312    (34%)              1931    (40%)                   <    0.001 
Angiotensin Receptor Blockers  321    (35%)              2185    (45%)                   <    0.001 
Digoxin 89     (10%)               447    (9%)                     0.68 
Beta-Blockers 684    (75%)              3866    (80%)                   <    0.001 
Calcium Channel Blockers 285    (31%)              1736    (36%)                   0.004 
Nitrate 182    (20%)              808    (17%)                    0.023 
Anticoagulant 242    (26%)              1277    (26%)                  0.95 
Aspirin 353    (38%)               1928    (40%)                   0.40 
Statin Lipid Lowering Medication 525    (57%)             2999    (62%)                   0.005 
Non-Statin Lipid Lowering Medication 48     (5%)                  270    (6%)                     0.66 
Combined statin/non-statin medication 540    (59%)              3087    (64%)                   0.003 
Antiplatelet Agent (excluding Aspirin) 115    (13%)             633    (13%)                      0.63 
ADP Antagonist 115    (13%)              633    (13%)                    0.63 
Automated Implantable Cardioverter 
Defibrillator 
0.3% 0.4%  
MAGGIC Risk Score n/a 20 ± 6  
  
Patients with LA Enlargement by any 
criteria (site-reported) 
n/a 99.6%  
Patients with wall thickness >= 1.2mm by 
any criteria (site-reported) 
n/a   
Structural heart disease by any criteria 
(site) 
n/a   
    
 







Table 2. Comparison of PARAGON with other HFpEF trials  
 PARAGON 
(n = 4822) 
TOPCAT Americas 
(n = 1767) 
I-Preserve 





(n = 850) 
Age 73 ± 8   72 (64, 79) 72±7 67 ± 11 75 (72, 79) 
Female Sex 52%  50% 60% 40% 56% 
NYHA 
Classification:2=CLASS II; 
3=CLASS III; 4=CLASS IV;   
 
    
2 72% 59% 22% 61% I/II =76% 
 
3 27% 35% 77% 38%  
4 0.6% 1% 3% 2% III/IV =25% 
Race 
 
    
ASIAN 13% 1% 1% 2% n/a 
BLACK 2% 17% 2% 4% n/a 
CAUCASIAN 82% 78% 93% 92% n/a 
NATIVE AMERICAN 1% 0.6%  0% n/a 
OTHER 3% 4% 4% 2% n/a 
Sitting Pulse Rate 
(beats/min): 
70 ± 12   68 (61, 76) 71±10 71±12 73 (66, 82) 
Sitting Systolic Blood 
Pressure (mmHg): 
136± 15 129 (118, 138) 136±15 136±18 139 (129, 
150) 
Sitting Diastolic Blood 
Pressure (mmHg): 
77 ± 11 70 (62, 80) 79±9 78±11 80 (74, 86) 
  
Ejection Fraction (%): 58 ± 8  58 (53, 64)   64 (56, 66) 
Body Mass Index (kg/m2): 30 ± 5 33 (28, 38) 30±5 29±6 28 (25, 30) 
Prior Heart Failure 
Hospitalization:0=N; 1=Y; 
48% 58.9% 23% 68.7%  
HHF > 9 Month prior to 
Screening 
38%  44% within 6 
months 
  
Hypertension 96% 90% 89% 64% 79% 
coronary artery disease 43% 32% 13% 33% CABG 20% 
PCI 8% 
Myocardial Infarction 23% 20% 23.5% 44% 27% 
Atrial Fibrillation/Atrial 
Flutter at Screening 
33%  34% 29% 29% 21% 
History of AF 52% 42% 29% 29%  
Left Bundle Branch Block 7%  8%   
Diabetes 43% 45% 27% 28% 21% 
Stroke 10% 9% 10% 9%  
Current Smoker 7% 7%  14%  
Glomerular Filtration Rate, 
Estimated (mL/min), 
Serum: 
61.3 (49, 75) 61 (49, 77) 73±23   
  
    
< 45 18% 17.7%    
>= 45, < 60 30% 31% 31%   
>= 60 53% 52%    
Diuretic 96% 89% Loop8 3% 
Thiazide 52% 





24%  15% 12%  
ACE-inhibitors 40% 50% 26% 19%  
Angiontensin receptor 
blockers 
45% 31%    
Digoxin 9%  14% 28% 12% 
Beta blockers 75% 79% 59% 56% 55% 
Calcium channel blockers 36% 39% 40% 31% 33% 
Nitrate 17% 17% 27% 33% 51% 
Anticoagulant 27%  19% 10% 16% 
Aspirin 40% 58%  58% 66% 
Statin Lipid Lowering 
Medication 
62% 65%    
Non-Statin Lipid Lowering 
Medication 
6% 13% 31% 42% 34% 
Antiplatelet Agent 
(excluding Aspirin) 
13%  59% 5%  
ADP Antagonist 13%     
Automated Implantable 
Cardioverter Defibrillator 
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